Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000703 · ClinicalTrials.gov registry record · NA
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
A NA study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 14
- Study locations
NCT00000703 is a NA study of HIV Infections and Lymphoma, Non-Hodgkin that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The trial reports 14 study locations across 7 states.
The verdict
NCT00000703, a NA study of HIV Infections and Lymphoma, Non-Hodgkin, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 14
- Study locations
Study Summary
To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma. Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results have not been satisfactory. This study will show whether the combination of chemotherapy, radiation, and AZT is more effective and less toxic than previously used treatments.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Allopurinol
- DRUG Doxorubicin hydrochloride
- DRUG Bleomycin sulfate
- DRUG Vincristine sulfate
Study Locations (14)
New York
- Bellevue Hosp / New York Univ Med Ctr - New York
- Saint Luke's - Roosevelt Hosp Ctr - New York
- Mount Sinai Med Ctr - New York
- Univ of Rochester Medical Center - Rochester
California
- Los Angeles County - USC Med Ctr - Los Angeles
- UCLA CARE Ctr - Los Angeles
- San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
Louisiana
- Charity Hosp / Tulane Univ Med School - New Orleans
- Louisiana State Univ Med Ctr / Tulane Med School - New Orleans
- Tulane Univ School of Medicine - New Orleans
District of Columbia
- George Washington Univ Med Ctr - Washington D.C.
Massachusetts
- Univ of Massachusetts Med Ctr - Worcester
Pennsylvania
- Milton S Hershey Med Ctr - Hershey
South Carolina
- Julio Arroyo - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Est. Completion | 1990-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000703
The ClinicalTrials.gov registry entry for NCT00000703 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00000703 reports 14 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00000703 about?
NCT00000703 is a clinical study titled "Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members". To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma. Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results have not been satisfactory. This study will show whether ...
What is the current status of trial NCT00000703?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. Estimated completion is 1990-03.
What conditions does trial NCT00000703 study?
This clinical trial studies the following conditions: HIV Infections, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT00000703?
The interventions under investigation include: Cyclophosphamide (DRUG), Allopurinol (DRUG), Doxorubicin hydrochloride (DRUG), Bleomycin sulfate (DRUG), Vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00000703?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000703 being conducted?
This trial has 14 study locations across California, District of Columbia, Louisiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.